Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: A multicenter case series

Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases

“…In our study, ICI-related severe blistering eruptions were not related to a specific type of cancer and were associated with any kind of ICI, used alone or in combination. The time from the first ICI-infusion to the onset of the cutaneous eruption was variable, ranging from 3 to 420 days (median 52 days), which is similar to previous reports [6,7]. Thus, facing such a cutaneous eruption with ICI, the search for causative drugs should not be restricted to the classical time to onset of drug reactions, especially in the case of EN presentation (for which the usual time to onset is 4–28 days) [11].…”

Immune checkpoint inhibitor-related Stevens-Johnson syndrome/toxic epidermal necrolysis-like reactions

“…To the Editor: We read with interest the article by Molina et al 1 that presented a series of 7 patients who developed Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)-like reactions in association with immune checkpoint inhibitors (ICI). The authors proposed the terminology ''progressive immunotherapy-related mucocutaneous eruption'' to differentiate this reaction from the classic SJS/ TEN based on certain differences in the clinical manifestations such as delayed onset from ICI initiation, mild initial presentation, rare ocular involvement, and a benign and favorable course.…”

Histopathologically‐confirmed lichenoid eruptions from immune checkpoint inhibitor therapy: a retrospective cohort analysis

“…Certain cirAE subtypes, such as progressive immunotherapy‐related mucocutaneous eruption, present as atypical variants of known dermatoses. Others, such as ICI‐induced lichenoid drug eruptions (ICI‐LDEs), can be clinically heterogeneous, complicating management 2–4 . Treatment paradigms for LDE from non‐ICI medications may not pertain to ICI‐LDE.…”

“…Others, such as ICI-induced lichenoid drug eruptions (ICI-LDEs), can be clinically heterogeneous, complicating management. [2][3][4] Treatment paradigms for LDE from non-ICI medications may not pertain to ICI-LDE.…”

“…1 In addition to survival, management of chronic diseases among survivors of cancer has emerged as a major concern, because survivors experience numerous sequelae and age-related conditions. 2 Psoriasis is a chronic inflammatory skin disorder that affects approximately 2-4% of the general population worldwide, and a recent population-based study found that the risk of cancer was higher in patients with psoriasis than in controls. 3 Conversely, one report found that the risk of psoriasis in patients with breast cancer was higher than in those who were generally healthy.…”